

Cardiomyopathy (DCM). Guo *et al.*, *Nat Med*, 18, 2012. However, it is unclear how RBM20 leads to disease presentation and progression. Thus, development of methods for screening and identifying compounds useful for modulating RBM20-associated cellular processes has been hindered.

[0005] All references cited herein, including patent applications and publications, are incorporated by reference in their entirety.

BRIEF SUMMARY

[0005a] In an aspect of the present disclosure, there is provided a method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a RBM20 polypeptide (“RBM20 condensates”) in the cytoplasm of a cell, the method comprising:

- (a) admixing the compound and a composition comprising the cell,
 - wherein (i) the cell comprises the one or more RBM20 condensates, and/or (ii) the one or more RBM20 condensates form in the cell after the compound contacts the composition;
 - (b) direct or indirect labeling of the RBM20 polypeptide;
 - (c) imaging at least a portion of the composition comprising the cell,
 - wherein detected light is due to direct labeling or indirect labeling of the RBM20 polypeptide, and
 - wherein the imaging provides data to assess the characteristic associated with the one or more RBM20 condensates; and
 - (d) determining the characteristic associated with the one or more RBM20 condensates in the cytoplasm using the imaging,
- wherein a modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more RBM20 condensates in the cytoplasm.

[0005b] In another aspect of the present disclosure, there is provided a method of identifying a compound useful for treating a RBM20-associated disease, the method comprising identifying a compound disclosed herein.